MDNA

Medicenna Therapeutics Corp. (MDNA) | Rumor.io

Medicenna Therapeutics

MDNA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MDNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Oct 27

Medicenna Therapeutics Corp. ($MDNA) has voluntarily delisted from the Nasdaq Stock Market due to significant costs and resources required for listing.
The company will maintain its listing on the Toronto Stock Exchange (TSX) and has sufficient cash to fund its operations beyond key value inflection milestones.
The delisting will result in the company's shares being traded on the OTC Markets, with the CEO expressing hope to return to the Nasdaq within a year.

Generated by AI

Sentiment

Of the messages about MDNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0%	0%	92.91% -5.8
Bearish	—	100%	100%	7.09% +5.8

Topics

Of the messages about MDNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	0%
Announcements	—	100%	100%	94.19%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	5.81%

Sep 13

Medicenna Therapeutics Corp. (MDNA) has announced a clinical collaboration with Merck to evaluate its MDNA11 candidate in combination with Merck's KEYTRUDA (pembrolizumab) in the ABILITY trial.
The collaboration aims to evaluate the combination of MDNA11 and KEYTRUDA in a range of cancers, with pre-clinical data suggesting potential synergies between the two treatments.
The partnership with Merck, a company with over $10 billion in cash on hand, is seen as a positive development for MDNA, providing access to a best-in-class PD-1 drug and a joint development committee to drive the collaboration forward.

Generated by AI

Community

Of the messages about MDNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	75%	82.35%	83.1%
Newcomers	100%	25%	17.65%	16.9%

Regulars· Feb 7

MDNA's CEO clarifies that the 5th cohort is not only the first 4 cohorts, with initial PK/PD data and anti-tumor activity data expected in Q1 2023.
MDNA will release data by the end of Q1 2023, including new scans from the first 4 cohorts and the 5th cohort, with the patients who had scans by then.
MDNA reported a loss of $0.01, beating consensus estimates of a loss of $0.06, according to Q3 2023 earnings results.

Newcomers· Dec 18

Newcomers are optimistic about $MDNA, predicting it will go "much higher" and calling the current price "easy money".
The initiation of coverage by Oppenheimer with an Outperform rating and a price target of $12 is seen as a positive development for $MDNA.
The relatively low float of 33M shares is noted as a potential factor contributing to $MDNA being "a bit underowned".

Generated by AI

HUYABIO International today announced statistically significant and clinically meaningful topline results from its global Phase 3 clinical trial evaluating HBI-8000 in combination with nivolumab for patients with advanced melanoma, bringing the company one step closer to a potential new frontline treatment option for one of the deadliest forms of skin cancer.

2mo agoYahoo Finance

Also Discussed

Investors talking about MDNA also mention

#	Name	Attention
1	NLTX - Neoleukin Therapeutics, Inc.	——
2	Cardiol Therapeutics Inc. Class A Common SharesCRDL	0%0
3	DiaMedica Therapeutics Inc.DMAC	0%0
4	APTO - Aptose Biosciences Inc.	——
5	BLPH - Bellerophon Therapeutics, Inc.	——
6	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
7	Alkermes plcALKS	0%0
8	CWBR - CohBar, Inc.	——
9	AFMD - Affimed N.V.	——
10	Marker Therapeutics, Inc.MRKR	0%0